← Back to Search

Brachytherapy

HDR Brachytherapy for Prostate Cancer

Q: Is enrollment for this clinical research trial ongoing?

<p>The data on clinicaltrials.gov suggests that this trial, which was posted in July 2012 and last updated on May 2022, is not presently recruiting new participants. Nevertheless, there are 1,321 other trials accepting patients at the moment.</p>

N/A

Waitlist Available

Led By Hans Chung, MD

Research Sponsored by Sunnybrook Health Sciences Centre

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Staging CT or MRI (abdomen and pelvis) and bone scan negative for metastases

ECOG performance status 0-1

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

Study Summary

This trial is looking at the feasibility and toxicities of treating localized prostate cancer with radioactive seeds, in the hopes that this will be a less invasive option with fewer complications than other treatment options.

Who is the study for?

Men with isolated local recurrence of prostate cancer after initial radiation therapy, who have a solitary recurrence confirmed by MRI and biopsy, PSA levels below 10 ng/mL, prostate volume under 50cc, good performance status (ECOG 0-1), no metastases on CT/MRI or bone scan, manageable urinary symptoms (IPSS < 15), and no prior extensive prostate treatments like TURP or chemotherapy.Check my eligibility

What is being tested?

The trial is testing focal salvage HDR brachytherapy—a targeted internal radiation treatment where radioactive seeds are temporarily implanted in the prostate. This pilot study aims to assess how feasible this approach is and what side effects it might cause when treating only the affected part of the prostate.See study design

What are the potential side effects?

Potential side effects may include urinary issues due to irritation from the radioactive seeds, bowel problems if nearby tissues are affected by radiation, sexual dysfunction as a result of nerve damage near the treated area, and general discomfort associated with invasive procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My scans show no cancer spread to my abdomen, pelvis, or bones.

Select...

I am fully active or can carry out light work.

Select...

My prostate is smaller than 50cc.

Select...

My MRI shows a single cancer recurrence in my prostate.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of acute urinary and rectal toxicities

Secondary outcome measures

Acute and late urinary toxicities

Biochemical (ie. prostate specific antigen) disease free survival

Incidence of late urinary and rectal toxicities

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Focal salvage HDR prostate brachytherapyExperimental Treatment1 Intervention

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor

656 Previous Clinical Trials

1,550,562 Total Patients Enrolled

34 Trials studying Prostate Cancer

12,578 Patients Enrolled for Prostate Cancer

Canadian Association of Radiation OncologyIndustry Sponsor

7 Previous Clinical Trials

442 Total Patients Enrolled

4 Trials studying Prostate Cancer

192 Patients Enrolled for Prostate Cancer

Hans Chung, MDPrincipal InvestigatorSunnybrook Health Sciences Centre, Odette Cancer Centre

1 Previous Clinical Trials

30 Total Patients Enrolled

Media Library

Focal Salvage HDR Brachytherapy (Brachytherapy) Clinical Trial Eligibility Overview. Trial Name: NCT01583920 — N/A

Prostate Cancer Research Study Groups: Focal salvage HDR prostate brachytherapy

Prostate Cancer Clinical Trial 2023: Focal Salvage HDR Brachytherapy Highlights & Side Effects. Trial Name: NCT01583920 — N/A

Focal Salvage HDR Brachytherapy (Brachytherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01583920 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this clinical research trial ongoing?

"The data on clinicaltrials.gov suggests that this trial, which was posted in July 2012 and last updated on May 2022, is not presently recruiting new participants. Nevertheless, there are 1,321 other trials accepting patients at the moment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Focal Salvage HDR Brachytherapy for the Treatment of Prostate Cancer

Dr. Hans Chung 2012. "Focal Salvage HDR Brachytherapy for the Treatment of Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01583920.

All > Canada Prostate Cancer > Recurrent Prostate Cancer